[Informe de investigación] Se espera que el mercado de derivados del plasma sanguíneo alcance los 51.119,24 millones de dólares en 2028 desde los 29.886,12 millones de dólares en 2022; se estima que registrará una tasa compuesta anual del 9,4% entre 2022 y 2028.
Los derivados del plasma se obtienen a partir de proteínas plasmáticas explícitas mediante el ciclo de fraccionamiento. Los derivados del plasma sanguíneo contienen una gran cantidad de proteínas, sales, minerales, hormonas, vitaminas e inhibidores de proteasa. Así, se utilizan habitualmente para destruir virus que desencadenan trastornos hemorrágicos, hepatitis B, hepatitis C, hemofilia A, inmunodeficiencia, hipogammaglobulinemia, hemofilia B y virus de la inmunodeficiencia humana.
El mercado de derivados del plasma sanguíneo se segmenta en en función del tipo, aplicación, usuario final y geografía. Por geografía, el mercado está ampliamente segmentado en América del Norte, Europa, Asia Pacífico, Medio Oriente y Asia. África y el Sur y el Sur. Centroamérica. El informe ofrece información y un análisis en profundidad del mercado, haciendo hincapié en parámetros como las tendencias del mercado, los avances tecnológicos y la dinámica del mercado, junto con el análisis del panorama competitivo de los principales actores del mercado del mundo.
Plasma sanguíneo Mercado de derivados: conocimientos estratégicos
regiones lucrativas para el mercado de derivados del plasma sanguíneo
conocimientos del mercado: Mercado de derivados del plasma sanguíneo
Aumento del uso de inmunoglobulina G en múltiples tratamientos para ofrecer oportunidades para el mercado de derivados del plasma sanguíneo en los próximos años
Las terapias con inmunoglobulina G (IgG) se utilizan ampliamente para tratar el sistema inmunológico primario Deficiencia causada por defectos genéticos. La demanda de IgG ha aumentado constantemente durante los últimos años debido al creciente conocimiento de la terapia con IgG. Según ensayos controlados realizados por Network Meta Analysis (NMA), la terapia con IgG ha sido aprobada para el tratamiento de la enfermedad de Guillain-barré. (SGB), polineuropatía desmielinizante inflamatoria crónica (PDIC), neuropatía motora multifocal (MMN) y dermatomiositis. Las terapias con IgG también son eficaces para tratar las exacerbaciones de la miastenia gravis y el síndrome de la persona rígida. Además, proporciona una eficacia convincente en trastornos autoinmunes como epilepsia, neuromielitis y encefalitis autoinmune.
- En 2022, Grifols firmó un acuerdo con Canadian Blood Services. Este acuerdo acelera la autosuficiencia en inmunoglobulinas de Canadá. Según el acuerdo, Grifols trabajará con Canadian Blood Services para aumentar gradualmente el suministro de plasma en Canadá hasta alcanzar volúmenes de 2,4 millones de gramos de medicamentos Ig al año en 2026.
- En 2021, la Administración de Alimentos y Medicamentos ( Cutaquig aprobado por la FDA para uso médico. Se utiliza como terapia de reemplazo para la inmunodeficiencia humoral primaria (IP) en adultos y pacientes pediátricos de 2 años o más. Cutaquig es una solución de inmunoglobulina lista para usar para infusión subcutánea. El producto está disponible en viales de un solo uso de 1 g, 1,65 g, 2 g, 3,3 g, 4 g u 8 g.
- En agosto de 2020, Kedrion Biopharma (Italia) comenzó a mejorar un tratamiento inferido de plasma para tratar la COVID. -19 pacientes. El tratamiento podría estar disponible para los pacientes en tres años y medio.
Una gran proporción de IgG se utiliza en especialidades fuera de la inmunología, como oncología, neurología, hematología y reumatología. En comparación con todas, la neurología es la especialidad de más rápido crecimiento en el mercado global. El crecimiento del mercado de inmunoglobulina G se atribuye a su aprobación para su uso según la etiqueta para la polineuropatía desmielinizante inflamatoria crónica (PDIC), seguida de su uso no autorizado en deficiencias inmunes secundarias causadas por linfoma, mieloma y leucemia y ciertas terapias inmunosupresoras, especialmente. Terapias dirigidas a células B. Por lo tanto, la amplia gama de uso de IgG en múltiples tratamientos para prescripciones dentro y fuera de etiqueta impulsará la demanda de IgG en todo el mundo en los próximos años.
Información del usuario final
Basado en Para el usuario final, el mercado mundial de derivados del plasma sanguíneo está segmentado en hospitales, clínicas y otros. El segmento de hospitales tuvo la mayor participación de mercado en 2022 y se prevé que registre la CAGR más alta durante el período de pronóstico. Se prevé que el creciente número de admisiones hospitalarias y la creciente prevalencia de la enfermedad de von Willebrand, los trastornos inmunodeficientes y la hemofilia impulsen el crecimiento del mercado para el segmento hospitalario durante el período de pronóstico. Además, las naciones emergentes están siendo testigos de una enorme demanda de entornos hospitalarios avanzados para hacer frente al creciente número de pacientes y las crecientes preocupaciones de salud pública. Además, en los hospitales se llevan a cabo diversas terapias de reemplazo de inmunoglobulinas para observar las dosis y los eventos adversos relacionados con la terapia y monitorear los resultados clínicos del producto. Los hospitales son centros primarios para brindar terapias de reemplazo de inmunoglobulinas, que se están desarrollando utilizando nuevas tecnologías. Los pacientes que reciben terapias con inmunoglobulinas en los hospitales perciben las ventajas de una mayor seguridad, un seguimiento más estrecho y el apoyo de profesionales y expertos de la salud. Por lo tanto, se espera que los beneficios proporcionados por los hospitales, como una atención adecuada centrada en el paciente y la disponibilidad de servicios de reembolso, impulsen el crecimiento del mercado para el segmento durante el período de pronóstico.
Mercado de derivados del plasma sanguíneo, por usuario final y ndash ; 2022 y 2028
Los lanzamientos de productos, fusiones y adquisiciones se encuentran entre las estrategias más adoptadas por los actores del mercado mundial de derivados del plasma sanguíneo. A continuación se enumeran algunos de los desarrollos de productos clave más recientes:
- En abril de 2022, Grifols anunció la finalización de la adquisición del 100% del capital social de Tiancheng (Alemania) Pharmaceutical Holdings AG. Tiancheng (Alemania) Pharmaceutical Holdings AG es una empresa alemana que posee el 89,88% de las acciones ordinarias y el 1,08% de las acciones preferentes de Biotest AG. Tras la finalización de la Oferta Pública de Adquisición (PTO) y el cierre de la adquisición, Grifols controla el 96,20% de los derechos de voto y posee el 69,72% del capital social de Biotest AG.
Derivados del plasma sanguíneo – Segmentación del mercado
Según el tipo, el mercado de derivados del plasma sanguíneo se segmenta en albúmina, factor VIII, factor IX, inmunoglobulina, globulina hiperinmune y otros. El mercado para el segmento de inmunoglobulinas se segmenta aún más en IgG, IgM, IgA, IgD e IgE. Por aplicación, el mercado de derivados del plasma sanguíneo se segmenta en hemofilia, hipogammaglobulinemia, enfermedades de inmunodeficiencia, enfermedad de von Willebrand y otras aplicaciones. El mercado, por usuario final, se segmenta en hospitales, clínicas y otros. Según la geografía, el mercado de derivados del plasma sanguíneo está segmentado en América del Norte (EE. UU., Canadá y México), Europa (Francia, Alemania, Reino Unido, Italia, España y el resto de Europa), Asia Pacífico (China, Japón , India, Australia, Corea del Sur y el resto de Asia Pacífico), Oriente Medio y Asia. África (Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos y el resto de Medio Oriente y África) y Sur y África. Centroamérica (Brasil, Argentina y el resto de América Central y del Sur).
Perfiles de empresas: Mercado de Derivados del Plasma Sanguíneo
- Grifols, SA
- SK Plasma Co., Ltd.
- Fusion Healthcare
- Biotest AG< /li>
- Green Cross Corp
- Kedrion
- LFB SA
- Octapharma AG
- CSL Limited
- Takeda Pharmaceutical Company Limited
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Blood plasma is the liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains blood pressure and helps exchange important minerals such as sodium and potassium for maintaining the body's pH balance. Plasma derivatives are products manufactured from human plasma using plasma fractionation techniques. These derivatives include albumin, factor VIII & IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins, including Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.
The factors that are driving the growth of market are increasing prevalence of blood disorders across the world followed by rising geriatric population. However, high cost of blood plasma therapy followed by complicated reimbursement policies are the major factor hampering the growth of the market.
The blood plasma derivative market majorly consists of the players such as Grifols, S.A., SK Plasma Co., Ltd., Fusion Healthcare, Biotest AG, Green Cross Corp, Kedrion, LFB S.A., Octapharma AG, CSL Limited, and Takeda Pharmaceutical Company Limited.
The blood plasma derivative market is analyzed in the basis of type, application, and end use. Based on type, is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulins segment held the largest share of the blood plasma derivative market size, and it is anticipated to register the highest CAGR.
The List of Companies - Blood Plasma Derivatives Market
- Grifols SA
- SK Plasma Co Ltd
- Octapharma AG
- Monobind Inc
- Intas Pharmaceuticals Ltd
- Fusion Health Care Pvt Ltd
- Takeda Pharmaceutical Co Ltd
- CSL Behring LLC
- LFB SA
- Kedrion SpA
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2023
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Mar 2023
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Mar 2023
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Mar 2023
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Mar 2023
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Mar 2023
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)